Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 8163 results

  1. Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)

    NICE is unable to make a recommendation on sebelipase alfa (Kanuma) for treating lysosomal lipase deficiency that is not Wolman disease in adults. The Wolman disease population was evaluated separately in NICE highly specialised technology guidance on sebelipase alfa (HST30). The cost effectiveness of the remaining non-Wolman population has not been demonstrated at this stage.

    Sections for TA961

  2. Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)

    NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.

    Sections for TA965

  3. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

  4. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals

  5. Support a quality standard

    Find out more about supporting a quality standard at NICE.

  6. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

  7. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  8. Committee D members

    Find out more about NICE technology appraisals advisory committee D members

  9. Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)

    NICE is unable to make a recommendation on satralizumab (Enspryng) for preventing relapses in neuromyelitis optica spectrum disorders in adults

    Sections for TA960

  10. Technology appraisal guidance

    Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

  11. Technology appraisal guidance

    Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS. These can be: medicines medical

  12. UK licensing and technology appraisals

    What we do NICE has a key role in the evaluation of and access to new and innovative medicines and treatments for the health system, playing an...

  13. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence

  14. Medical technologies advisory committee

    Information, meeting dates and minutes of the medical technologies advisory committee

  15. Medical technologies advisory committee members

    Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob

  16. Timeline for developing quality standards

    The key stages of development for quality standards

  17. Desflurane for maintenance of anaesthesia (ES41)

    Summary of the evidence on desflurane for maintenance of anaesthesia

  18. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  19. Managed access

    Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  20. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people....

  21. Charging for technology appraisals and highly specialised technologies

    Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.

  22. Interventional procedures advisory committee

    Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.

  23. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  24. Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

    Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.

  25. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  26. Public board meetings

    Agenda and papers of the NICE public board meeting on 20 March 2024

  27. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  28. NICE guidance

    We use the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms. From this page, you can find

  29. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  30. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  31. Technology appraisal committee

    Details, meeting dates and minutes of the independent technology appraisal committees

  32. Public board meetings

    Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.

  33. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTE5)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....

  34. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  35. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  36. Our projects and partners

    NICE research projects and partners.

  37. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  38. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.

  39. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

  40. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  41. Guides to developing our guidance

    Resources to help organisations who want to help develop NICE guidance

  42. Register as a stakeholder

    Take part in the production of medical technologies guidance.

  43. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  44. 25,000 people to benefit after NICE recommends new ulcerative colitis treatment

    New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA

  45. Bringing our guidance together by topic

    We're bringing our guidance together by topic, so that it's all in one place, clearer to understand and easier to access. We expect that this will...

  46. Board, executive team and senior leaders interests register

    This register shows current declarations of interest made by our: non-executive directors executive team members senior leaders. We publish it

  47. Changes to charging for Technology Appraisal and Highly Specialised Technologies consultation

    Take part in our consultation: 5 proposals about the way the NICE charges for TAs and HSTs.

  48. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  49. Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

    Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.

  50. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.